3692 — Hansoh Pharmaceutical Balance Sheet
0.000.00%
- HK$102.57bn
- HK$80.46bn
- CNY10.10bn
- 87
- 22
- 95
- 81
Annual balance sheet for Hansoh Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 14,594 | 13,718 | 18,933 | 21,623 | 24,857 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,279 | 3,210 | 3,782 | 3,674 | 3,321 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 17,448 | 17,286 | 23,179 | 25,832 | 28,883 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,123 | 3,468 | 3,569 | 3,483 | 3,294 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 19,575 | 20,792 | 27,160 | 30,002 | 33,039 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6,240 | 2,690 | 3,024 | 2,620 | 6,863 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 6,531 | 2,916 | 7,131 | 7,355 | 7,244 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 13,044 | 17,876 | 20,029 | 22,647 | 25,795 |
Total Liabilities & Shareholders' Equity | 19,575 | 20,792 | 27,160 | 30,002 | 33,039 |
Total Common Shares Outstanding |